<DOC>
	<DOCNO>NCT00327535</DOCNO>
	<brief_summary>This 4 arm study ass optimal start dose Mircera treatment anemia patient non-small cell lung cancer receive first line myelosuppressive chemotherapy . Patients randomize receive either Mircera 6.3 micrograms/kg , 9 micrograms/kg 12 micrograms/kg s.c. every 3 week darbepoetin alfa accord approve local label ( either 6.75 micrograms/kg s.c. every 3 week , 2.25 micrograms/kg every week ) . The anticipated time study treatment &lt; 3 month target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Mircera Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>&gt; =18 year age ; stage III IV nonsmall cell lung cancer receive first line myelosuppressive chemotherapy ; myelosuppressive chemotherapy schedule least 9 week ; anemia screen visit . transfusion red blood cell 4 week prior first plan dose study medication ; iron deficiency anemia , anemia cause gastrointestinal bleeding ; prior treatment Mircera .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>